Atticus in the News
Atticus Pharma is a therapeutics company developing drugs for immunodermatology and associated diseases. Our two initial programs are for the treatment of cutaneous lupus lesions and androgenic alopecia. Atticus licensed from Zylö Therapeutics the Z-pod® sustained-release technology that originated at Albert Einstein College of Medicine that was further developed at Zylö. The technology provides a depot-like effect and enables delivery of therapeutic agents (small molecules, peptides, siRNA) in a sustained-release manner.
Atticus Pharma Announces Clinical Data for ATC-002, a Pharmaceutical Product Candidate for Androgenic Alopecia
GREENVILLE, SC, UNITED STATES, February 11, 2026 /EINPresswire.com/ --
​
• ATC-002 is a topical treatment designed to stimulate new hair growth in subjects with androgenic alopecia.
• ATC-002 uses Atticus’s proprietary Z-pod® technology to create a drug depot in the hair follicle and stratum corneum to deliver drug in a sustained-release manner.
• ATC-002 was evaluated in a cosmetic claims substantiation clinical trial in a 6-month, 3-arm, randomized, double-blind, placebo-controlled study in 98 women in the U.S.
• This First-in-Human study provided clear evidence of therapeutic effect and unremarkable safety and tolerability, both supporting continued clinical development.
​
Atticus Pharma Inc., a therapeutics company focused on immunodermatology and other skin disorders, today announced data from a clinical study of ATC-002 in females with androgenic alopecia. ATC-002 is a proprietary product candidate that delivers a mitochondrial-activating molecule using Atticus’s Z-pod sustained-release technology.
The study was a 6-month, 3-arm, randomized, double-blind, placebo-controlled study in 98 women in the U.S. Subjects were randomly assigned to receive: (i) a low dose of ATC-002, (ii) a high dose of ATC-002, or (iii) placebo. The main objectives of the study were to assess systemic safety and local tolerability as well as exploring dose response and subject baseline characteristics associated with optimal therapeutic response.
Overall, all study treatments were safe and well tolerated. Topical application of ATC-002 was associated with terminal hair growth at both doses. In particular, the high dose resulted in a mean increase of 13.8 hairs/cm2 in subjects with more hair loss as measured by vellus to terminal hair ratios. The increase in hair growth continued between the 3-month and the final 6-month timepoints, suggesting that future trials of longer duration will show even greater gains. Importantly, the study subject’s global satisfaction questionnaire was highly consistent with the objective hair count findings.
“Demonstrating significant new hair growth in androgenic alopecia subjects that had a challenging baseline ratio of vellus to terminal hair is exciting,” said Atticus CEO, Leigh Hsu, Ph.D. “We are extremely pleased with the findings from this study as they inform the next stage of clinical development and supports a clear regulatory pathway for a future Rx that can treat a condition affecting 80 million Americans.” Hsu added, “It’s also very encouraging that ATC-002 safety and tolerability were unremarkable because drugs for androgenic alopecia are generally used long-term, so a clean safety profile is critical to assure treatment compliance.”
​
​
Atticus Pharma Completes Enrollment in the First Human Clinical Trial of ATC-002 for Androgenic Alopecia
Greenville, South Carolina, June 16, 2025 – Atticus Pharma Inc., a therapeutics company focused on immunodermatology and associated conditions, today announced completion of subject enrollment in the human clinical study of ATC-002 in females diagnosed with androgenic alopecia. As planned, a total of 96 subjects were enrolled and randomly assigned to receive: (i) a low dose of ATC-002, (ii) a high dose of ATC-002, or (iii) placebo.
ATC-002 is a proprietary product candidate that delivers a mitochondrial-activating molecule using Atticus’s Z-pod sustained-release technology. Participating subjects will be returning for their interim 90-day efficacy and safety assessments, with the first study readout planned in Q3 later this year and with final data in Q4.
“We are pleased to have met the enrollment target in less than eight weeks,” said Atticus CEO, Leigh Hsu, Ph.D. “The enrollment milestone underscores the tremendous need and commercial market potential for a differentiated treatment for androgenic alopecia, which affects approximately 80 million people in the United States. Due to potential side effects associated with current treatments, women are often left without a good treatment option and positive data from our trial would provide a pathway for future Rx development of a much-needed new
product.”
Atticus Pharma Announces Late-Breaking Presentation of Collaborative Research at the 82nd Annual SID 2025
GREENVILLE, SC, UNITED STATES, May 5, 2025 /EINPresswire.com/ -- Atticus Pharma Inc, a therapeutics company focused on immunodermatology and associated conditions, today announced the presentation of pre-clinical results in a novel murine model of cutaneous lupus. The poster presentation, co-authored by researchers from University of Pennsylvania Perelman School of Medicine, the Philadelphia VA Medical Center, Zylo Therapeutics and Atticus Pharma, will be made at the 2025 Annual Meeting of the Society for Investigational Dermatology, taking place May 7-10, in San Diego, California.
The presentation highlights collaborative research contributing to Atticus’s ATC-001 product candidate for cutaneous lupus erythematosus, now entering IND-enabling studies, with preclinical models and expertise from the University of Pennsylvania and the Philadelphia VAMC and under the guidance of Victoria Werth, M.D.
​
SID 2025 Presentation Details
• Poster Number: LB1261
• Title: Therapeutic effects of nano-encapsulated anandamide on skin inflammation in a novel PD-1H knock-out lupus mouse model
• Date: Thursday May 8, 2025
• Time: 4:30 – 6:00 p.m. PST
• Location: Hilton San Diego Bayfront, San Diego, California (Indigo Ballroom & Foyer – Floor Level 2)
Atticus Initiates Clinical Study for ATC-002 in Androgenic Alopecia
GREENVILLE - (EIN Presswire) - April 14, 2025. Atticus Pharma Inc, a therapeutics company focused on immunodermatology and associated conditions, today announced the initiation of a human clinical study of ATC-002 in androgenic alopecia. ATC-002 is a proprietary product candidate that delivers a mitochondrial-activating molecule using Atticus’s Z-pod sustained-release technology. Several subjects have been screened and have received ATC-002.
Atticus accepted into NYU's Endless Frontier Labs [EFL] Mentorship Program
Only 78 of over 1,400 applicants accepted into this prestigious program that is designed to optimize each startup’s chance of scaling into a successful company.
